MX2022012095A - Moduladores de alfa-1-antitripsina. - Google Patents
Moduladores de alfa-1-antitripsina.Info
- Publication number
- MX2022012095A MX2022012095A MX2022012095A MX2022012095A MX2022012095A MX 2022012095 A MX2022012095 A MX 2022012095A MX 2022012095 A MX2022012095 A MX 2022012095A MX 2022012095 A MX2022012095 A MX 2022012095A MX 2022012095 A MX2022012095 A MX 2022012095A
- Authority
- MX
- Mexico
- Prior art keywords
- alpha
- antitrypsin
- tetrazatricyclo
- aatd
- indazole
- Prior art date
Links
- QEJZWZRHKLWLEZ-UHFFFAOYSA-N pyrrolo[2,3-f]indazole Chemical compound N1=NC=C2C=C3C(C=C12)=CC=N3 QEJZWZRHKLWLEZ-UHFFFAOYSA-N 0.000 title abstract 2
- 102000015395 alpha 1-Antitrypsin Human genes 0.000 title 1
- 108010050122 alpha 1-Antitrypsin Proteins 0.000 title 1
- 208000006682 alpha 1-Antitrypsin Deficiency Diseases 0.000 title 1
- 229940024142 alpha 1-antitrypsin Drugs 0.000 title 1
- 239000002753 trypsin inhibitor Substances 0.000 abstract 2
- 230000007812 deficiency Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H17/00—Compounds containing heterocyclic radicals directly attached to hetero atoms of saccharide radicals
- C07H17/02—Heterocyclic radicals containing only nitrogen as ring hetero atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/02—Local antiseptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Nutrition Science (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Compuestos, composiciones y métodos novedosos para usar y preparar los mismos, que pueden ser útiles para tratar la deficiencia de alfa-1-antitripsina (AATD).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063004636P | 2020-04-03 | 2020-04-03 | |
| PCT/US2021/025597 WO2021203010A1 (en) | 2020-04-03 | 2021-04-02 | Pyrrolo[2,3-f]indazole and 2,4,5,10-tetrazatricyclo[7.3.0.03,7]dodeca-1,3(7),5,8,11-pentaene derivatives as alpha-1-antitrypsin modulators for treating alpha-1-antitrypsin deficiency (aatd) |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022012095A true MX2022012095A (es) | 2023-01-11 |
Family
ID=75690656
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022012095A MX2022012095A (es) | 2020-04-03 | 2021-04-02 | Moduladores de alfa-1-antitripsina. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20230159580A1 (es) |
| EP (1) | EP4126877A1 (es) |
| JP (1) | JP2023520398A (es) |
| KR (1) | KR20220163429A (es) |
| CN (1) | CN115776984A (es) |
| AR (1) | AR121744A1 (es) |
| AU (1) | AU2021247282A1 (es) |
| BR (1) | BR112022019794A2 (es) |
| CA (1) | CA3179184A1 (es) |
| IL (1) | IL296750A (es) |
| MX (1) | MX2022012095A (es) |
| TW (1) | TW202204359A (es) |
| WO (1) | WO2021203010A1 (es) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020081257A1 (en) | 2018-10-05 | 2020-04-23 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| UY38696A (es) | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
| US20240012010A1 (en) | 2020-11-12 | 2024-01-11 | Vertex Pharmaceuticals Incorporated | Methods of monitoring alpha-1 antitrypsin (aat) deficiency by measuring polymerised aat |
| WO2024054624A1 (en) | 2022-09-09 | 2024-03-14 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3103920A1 (en) * | 2018-06-22 | 2019-12-26 | Ucl Business Ltd | Compounds for treating alpha-1 antitrypsin-mediated diseases |
| WO2020081257A1 (en) * | 2018-10-05 | 2020-04-23 | Vertex Pharmaceuticals Incorporated | Modulators of alpha-1 antitrypsin |
| UY38696A (es) * | 2019-05-14 | 2020-11-30 | Vertex Pharma | Moduladores de alfa-1 antitripsina |
| TW202116303A (zh) * | 2019-10-02 | 2021-05-01 | 美商維泰克斯製藥公司 | α—１抗胰蛋白酶缺乏症之治療方法 |
-
2021
- 2021-04-02 CA CA3179184A patent/CA3179184A1/en active Pending
- 2021-04-02 WO PCT/US2021/025597 patent/WO2021203010A1/en active Application Filing
- 2021-04-02 EP EP21722013.6A patent/EP4126877A1/en active Pending
- 2021-04-02 BR BR112022019794A patent/BR112022019794A2/pt unknown
- 2021-04-02 AU AU2021247282A patent/AU2021247282A1/en active Pending
- 2021-04-02 KR KR1020227038218A patent/KR20220163429A/ko unknown
- 2021-04-02 JP JP2022559584A patent/JP2023520398A/ja active Pending
- 2021-04-02 CN CN202180039946.7A patent/CN115776984A/zh active Pending
- 2021-04-02 IL IL296750A patent/IL296750A/en unknown
- 2021-04-02 US US17/916,481 patent/US20230159580A1/en active Pending
- 2021-04-02 MX MX2022012095A patent/MX2022012095A/es unknown
- 2021-04-05 AR ARP210100864A patent/AR121744A1/es unknown
- 2021-04-06 TW TW110112373A patent/TW202204359A/zh unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AR121744A1 (es) | 2022-07-06 |
| JP2023520398A (ja) | 2023-05-17 |
| WO2021203010A1 (en) | 2021-10-07 |
| KR20220163429A (ko) | 2022-12-09 |
| AU2021247282A1 (en) | 2022-10-27 |
| IL296750A (en) | 2022-11-01 |
| BR112022019794A2 (pt) | 2022-12-06 |
| TW202204359A (zh) | 2022-02-01 |
| CN115776984A (zh) | 2023-03-10 |
| US20230159580A1 (en) | 2023-05-25 |
| EP4126877A1 (en) | 2023-02-08 |
| CA3179184A1 (en) | 2021-10-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2022012095A (es) | Moduladores de alfa-1-antitripsina. | |
| JOP20200178A1 (ar) | حلقات ضخمة كمعدلات لمنظم توصيل التليف الكيسي عبر الغشاء، وتركيبات صيدلانية منها، واستخدامها في علاج التليف الكيسي، وعملية لتصنيعها | |
| MX2021003819A (es) | Moduladores de alfa-1 antitripsina. | |
| WO2007059202A3 (en) | Pyrazolyl urea derivatives useful in the treatment of cancer | |
| MX2022006865A (es) | Tetrahidrofuranos sustituidos como moduladores de canales de sodio. | |
| TW200718689A (en) | 2-Amino-quinazolin-5-ones | |
| IN2014KN02886A (es) | ||
| WO2006105403A3 (en) | Treatment of eye disorders with sirtuin modulators | |
| MX2010002318A (es) | Derivados azaindol 2,3-sustituidos para tratar infecciones virales. | |
| CY1112478T1 (el) | Ενωσεις κιναζολινονης ως αντικαρκινικοι παραγοντες | |
| WO2006127987A3 (en) | Treatment of eye disorders with sirtuin modulators | |
| IL204763A (en) | Kinazolinone derivatives preserved at position 6, 7, or 8, their composition and @ methods of use @ them | |
| SI1789419T1 (sl) | Girazni inhibitorji in njihove uporabe | |
| PT2383271E (pt) | Aminoquinolonas como inibidores de gsk-3 | |
| WO2007120333A3 (en) | Tetracyclic kinase inhibitors | |
| MX2008008556A (es) | Derivados de triterpenoquinonas y triterpenofenoles y su aplicacion para el tratamiento de tumores y enfermedades parasitarias. | |
| MX2021006884A (es) | Compuestos y su uso para el tratamiento de la deficiencia de alfa1-antitripsina. | |
| CR20230100A (es) | Compuestos fosfolípidos y usos de los mismos | |
| MX2008015775A (es) | Compuestos y composiciones para tratamiento de cancer. | |
| CR20230164A (es) | Compuestos fosfolípidos y usos de estos | |
| AU2001292579A1 (en) | Methods and compounds for treating proliferative diseases | |
| WO2006102375A3 (en) | Methods for avoiding edema in the treatment or prevention of pparϝ-responsive diseases, including cancer | |
| MXPA05011785A (es) | Moduladores positivos de receptores de acetilcolina nicotinicos. | |
| EA202191984A1 (ru) | Фармацевтическая композиция, содержащая ингибитор flt3 и гипометилирующий агент, для лечения острого миелолейкоза | |
| WO2023122260A3 (en) | Inhibitors of sars-cov-2 |